This section of the FEDERAL REGISTER

contains regulatory documents having general

applicability and legal effect, most of which

are keyed to and codified in the Code of

Federal Regulations, which is published under

50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by

the Superintendent of Documents. Prices of

new books are listed in the first FEDERAL

REGISTER issue of each week.

Rules and Regulations Federal Register

11075 

Vol. 76, No. 40 

Tuesday, March 1, 2011 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

21 CFR Part 1308 

[Docket No. DEA–345F] 

Schedules of Controlled Substances: 

Temporary Placement of Five 

Synthetic Cannabinoids Into 

Schedule I 

AGENCY: Drug Enforcement 

Administration (DEA), U.S. Department 

of Justice. 

ACTION: Final order. 

SUMMARY: The Administrator of the Drug 

Enforcement Administration (DEA) is 

issuing this final order to temporarily 

place five synthetic cannabinoids into 

the Controlled Substances Act (CSA) 

pursuant to the temporary scheduling 

provisions. The substances are 1-pentyl3-(1-naphthoyl)indole (JWH–018), 1- 

butyl-3-(1-naphthoyl)indole (JWH–073), 

1-[2-(4-morpholinyl)ethyl]-3-(1- 

naphthoyl)indole (JWH–200), 5-(1,1- 

dimethylheptyl)-2-[(1R,3S)-3- 

hydroxycyclohexyl]-phenol (CP– 

47,497), and 5-(1,1-dimethyloctyl)-2- 

[(1R,3S)-3-hydroxycyclohexyl]-phenol 

(cannabicyclohexanol; CP–47,497 C8 

homologue). This action is based on a 

finding by the Administrator that the 

placement of these synthetic 

cannabinoids into Schedule I of the CSA 

is necessary to avoid an imminent 

hazard to the public safety. As a result 

of this order, the full effect of the CSA 

and its implementing regulations 

including criminal, civil and 

administrative penalties, sanctions and 

regulatory controls of Schedule I 

substances will be imposed on the 

manufacture, distribution, possession, 

importation, and exportation of these 

synthetic cannabinoids. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, PhD, Chief, Drug 

and Chemical Evaluation Section, Office 

of Diversion Control, Drug Enforcement 

Administration, 8701 Morrissette Drive, 

Springfield, VA 22152, telephone (202) 

307–7183, fax (202) 353–1263, or e-mail 

ode@usdoj.gov. 

DATES: Effective Date: March 1, 2011. 

SUPPLEMENTARY INFORMATION: 

Background 

The Comprehensive Crime Control 

Act of 1984 (Pub. L. 98–473), which was 

signed into law on October 12, 1984, 

amended section 201 of the CSA (21 

U.S.C. 811) to give the Attorney General 

the authority to temporarily place a 

substance into Schedule I of the CSA for 

one year without regard to the 

requirements of 21 U.S.C. 811(b) if he 

finds that such action is necessary to 

avoid imminent hazard to the public 

safety. The Attorney General may 

extend the temporary scheduling up to 

six months during pendency of 

proceedings under 21 U.S.C. 811(a)(1). 

A substance may be temporarily 

scheduled under the emergency 

provisions of the CSA if it is not listed 

in any other schedule under section 202 

of the CSA (21 U.S.C. 812) or if there is 

no exemption or approval in effect 

under 21 U.S.C. 355 for the substance. 

The Attorney General has delegated his 

authority under 21 U.S.C. 811 to the 

DEA Administrator (28 CFR 0.100). 

As per section 201(h)(4) of the CSA 

(21 U.S.C. 811(h)(4)), the Deputy 

Administrator, now Administrator, 

transmitted notice of her intention to 

temporarily place JWH–018, JWH–073, 

JWH–200, CP–47,497, and 

cannabicyclohexanol into Schedule I of 

the CSA to the Assistant Secretary for 

Health of the Department of Health and 

Human Services (HHS) in a letter dated 

October 6, 2010. In response to this 

notification, the Assistant Secretary of 

Health, HHS communicated in a letter 

dated November 22, 2010, to the thenDEA Acting Administrator that there are 

no exemptions or approvals in effect for 

JWH–018, JWH–073, JWH–200, CP– 

47,497, and cannabicyclohexanol under 

Section 505 of the Federal Food, Drug 

and Cosmetic Act (21 U.S.C. 355). The 

substances are not listed in any other 

schedule in 21 U.S.C. 812. 

A notice of intent to temporarily place 

JWH–018, JWH–073, JWH–200, CP– 

47,497, and cannabicyclohexanol into 

Schedule I of the CSA was published in 

the Federal Register on November 24, 

2010 (75 FR 71635). Before making a 

finding that temporarily placing a 

substance into Schedule I of the CSA is 

necessary to avoid an imminent hazard 

to the public safety, the Administrator 

must consider three of the eight factors 

(factors 4, 5, and 6) set forth in section 

201(c) of the CSA (21 U.S.C. 811(c)). 

These factors are the history and current 

pattern of abuse, the scope, duration, 

and significance of abuse, and what, if 

any, risk there is to the public health, 

including actual abuse, diversion from 

legitimate channels, and clandestine 

importation, manufacture, or 

distribution. 21 U.S.C. 811(h)(3). 

The temporary placement of these five 

synthetic cannabinoids into Schedule I 

of the CSA is necessary in order to avoid 

an imminent hazard to the public safety. 

First, these substances are not intended 

for human consumption, but there has 

been a rapid and significant increase in 

abuse of these substances in the United 

States. As a result of this abuse, 

synthetic cannabinoids are banned in at 

least 18 states in the United States and 

several countries, and all five branches 

of the U.S. military prohibit military 

personnel from possessing or using 

synthetic cannabinoids. Second, law 

enforcement has seized synthetic 

cannabinoids in conjunction with 

controlled substances and based on selfreports to law enforcement and health 

care professionals, synthetic 

cannabinoids are abused for their 

psychoactive properties. Third, 

numerous state and local public health 

departments and poison control centers 

have issued health warnings describing 

the adverse health effects associated 

with synthetic cannabinoids. Based on 

scientific data currently available, these 

five substances have the potential to be 

extremely harmful and, therefore, pose 

an imminent hazard to the public safety. 

History and Current Pattern of Abuse 

A ‘‘cannabinoid’’ is a class of chemical 

compounds in the marijuana plant that 

are structurally related. The 

cannabinoid D9-tetrahydrocannabinol 

(THC) is the primary psychoactive 

constituent of marijuana. ‘‘Synthetic 

cannabinoids’’ are a large family of 

chemically unrelated structures 

functionally (biologically) similar to 

THC, the active principle of marijuana. 

Two of the five synthetic 

cannabinoids (CP–47,497 and 

cannabicyclohexanol) were synthesized 

in the early 1980s for research purposes 

mstockstill on DSKH9S0YB1PROD with RULES

11076 Federal Register / Vol. 76, No. 40 / Tuesday, March 1, 2011 / Rules and Regulations 

in the investigation of the cannabinoid 

system. JWH–018, JWH–073, and JWH– 

200 were prepared in the mid-1990s and 

evaluated to further advance 

understanding of drug-receptor 

interactions regarding the cannabinoid 

system. Developed and evaluated as 

research tools, no other known 

legitimate uses have been identified for 

these five synthetic cannabinoids. 

Furthermore, these five synthetic 

cannabinoids are not intended for 

human consumption. 

The emergence of these five synthetic 

cannabinoids represents a recent 

phenomenon in the U.S. designer drug 

market. Since the initial identification 

of JWH–018 by U.S. forensic 

laboratories, many additional synthetic 

cannabinoids including JWH–073, 

JWH–200, CP–47,497, and 

cannabicyclohexanol have been 

identified in related herbal incense 

products and plant food. These 

synthetic cannabinoids have purported 

psychotropic effects when smoked or 

ingested. These substances are typically 

found in powder form or are dissolved 

in appropriate solvents, such as acetone, 

before being sprayed on the plant 

material contained in the herbal incense 

products. 

The popularity of these THC-like 

synthetic cannabinoids has significantly 

increased throughout the United States, 

and they are being abused for their 

psychoactive properties as reported by 

law enforcement, the medical 

community, and through scientific 

literature. 

Some of the product names include, 

but are not limited to, ‘‘Spice,’’ ‘‘K2,’’ and 

many more. Due to sophisticated 

marketing, the products that contain 

these five THC-like synthetic 

cannabinoids are perceived as ‘‘legal’’ 

alternatives to marijuana despite the fact 

that they are typically advertised as 

herbal incense or plant food (Bonsai-18) 

by Internet retailers, tobacco shops, 

head shops, and other domestic brick 

and mortar retail venues, and labeled 

‘‘Not For Human Consumption.’’ No 

evidence exists that these synthetic 

cannabinoids have value as an additive 

to herbal incense products due to the 

absence of odor associated with the 

substances. 

Based on law enforcement 

encounters, these five substances are 

typically found laced on plant material. 

The plant material is packaged in small 

pouches or packets, and is being sold 

over the Internet, in tobacco and smoke 

shops, drug paraphernalia shops, gas 

stations, and convenience stores as 

herbal incense products, giving 

customers of all ages direct access to 

these five substances. Research articles 

propose that the packaging is 

professional and conspicuous, targeting 

young people, possibly eager to use 

cannabis, but who are afraid of the 

judicial consequences and/or 

association with illicit drugs. 

According to Internet discussion 

boards and law enforcement encounters 

reported directly to DEA, these five 

synthetic cannabinoids are being both 

abused alone and/or being sprayed on 

plant material (which is then smoked). 

The most common route of 

administration of these synthetic 

cannabinoids is by smoking (using a 

pipe, a water pipe, or rolling the drugspiked plant material in cigarette 

papers). 

These five synthetic cannabinoids 

alone or spiked on plant material have 

the potential to be extremely harmful 

due to their method of manufacture and 

high pharmacological potency. There is 

little information regarding the 

pharmacology, toxicology, and safety of 

these substances in humans given the 

minimal amount of pre-clinical 

investigations undertaken regarding 

these substances; therefore, the full 

danger of these drugs has not yet been 

determined. 

As of January 31, 2011, 18 states in 

the United States and other countries 

have controlled one or more of the five 

synthetic cannabinoids. Moreover, all 

five branches of the military prohibit 

their personnel from possessing or using 

synthetic cannabinoids associated with 

products such as Spice and K2. 

Scope, Duration, and Significance of 

Abuse 

According to forensic laboratory 

reports, the initial appearance of these 

synthetic cannabinoids in herbal 

incense products in the United States 

occurred in November 2008 when U.S. 

Customs and Border Protection first 

encountered products such as Spice. 

The increasing abuse of the five 

synthetic cannabinoids is demonstrated 

by the increase in federal, state, and 

local law enforcement activity 

associated with these substances. The 

National Forensic Laboratory 

Information System, a national 

repository for drug evidence analyses 

from forensic laboratories across the 

United States, has reported in excess of 

500 exhibits containing synthetic 

cannabinoid from January 2010 through 

September 2010. These exhibits came 

from numerous states across the nation 

including Alabama, Arkansas, 

California, Florida, Hawaii, Iowa, 

Indiana, Kansas, Kentucky, Louisiana, 

Minnesota, Missouri, North Dakota, 

Nebraska, Nevada, Oklahoma, 

Pennsylvania, South Carolina, 

Tennessee, and Virginia. 

Even though there is no evidence of 

legitimate non-research related use for 

these synthetic cannabinoids, multiple 

shipments of JWH–018 and JWH–073 

have been encountered by U.S. Customs 

and Border Protection in 2010. One 

enforcement operation encountered five 

shipments of JWH–018 totaling over 50 

kilograms (110.2 pounds) of powder. In 

addition, bulk loads of JWH–018 and 

JWH–200 have been encountered by law 

enforcement in 2010. For example, in 

Casper, Wyoming, DEA agents 

encountered large quantities of herbal 

incense products laced with the 

synthetic cannabinoid JWH–018 in 

conjunction with methamphetamine 

and other illegal drugs in execution of 

search and arrest warrants. 

On March 24, 2010, the American 

Association of Poison Control Centers 

reported receiving 112 calls from 15 

states related to synthetic cannabinoids 

to U.S. poison centers since 2009. Just 

nine months later, the number of calls 

increased to over 2,700 from 49 states 

and the District of Columbia. 

What, If Any, Risk There Is to the 

Public Health 

Health warnings have been issued by 

numerous state and local public health 

departments and poison control centers 

describing the adverse health effects 

associated with these synthetic 

cannabinoids and their related products, 

including agitation, anxiety, nausea, 

vomiting, tachycardia (fast, racing 

heartbeat), elevated blood pressure, 

tremor, seizures, hallucinations, 

paranoid behavior, and nonresponsiveness. 

Smoking these synthetic cannabinoids 

for the purpose of achieving 

intoxication and experiencing the 

psychoactive effects has been identified 

as a reason for emergency room visits 

and calls to poison control centers. In a 

fact sheet by the National Drug Court 

Institute, the problem of synthetic 

cannabinoid abuse is described as 

‘‘significant and disturbing.’’ This is 

supported by information that was 

communicated to DEA from one of the 

major private toxicology laboratories. 

Based on laboratory findings from drug 

screens for the period of July 2010 

through November 2010, over 3,700 

specimens tested positive for either 

JWH–018 or JWH–073. They also 

indicated that they were finding 30– 

35% positivity for specimens submitted 

by juvenile probation departments. 

Case reports describe psychotic 

episodes, withdrawal, and dependence 

associated with use of these synthetic 

cannabinoids, similar to syndromes 

mstockstill on DSKH9S0YB1PROD with RULES

Federal Register / Vol. 76, No. 40 / Tuesday, March 1, 2011 / Rules and Regulations 11077 

observed in marijuana abuse. In 

addition, based on law enforcement 

encounters reported directly to DEA, 

when responding to incidents involving 

individuals who have reportedly 

smoked these synthetic cannabinoids, 

first responders report that these 

individuals have suffered from intense 

hallucinations. Moreover, emergency 

department physicians and toxicologists 

have reported the adverse health effects 

associated with smoking herbal incense 

products laced with these substances. 

Furthermore, based on law enforcement 

encounters, suspected Driving Under 

the Influence of Drug incidents are 

attributed to the smoking of synthetic 

cannabinoids. For example, in 

September 2010, police in Nebraska 

responded to an incident involving a 

teenage male who had careened his 

truck into the side of a residence. After 

striking the residence and several more 

items, the teen continued several more 

yards before coming to a complete stop. 

Prior to crashing the truck, the 

individual had driven past a junior high 

school and nearly struck a child. Upon 

further investigation, the driver of the 

vehicle admitted to smoking ‘‘Wicked 

X,’’ a product marketed as ‘‘herbal 

incense’’ and known to contain 

synthetic cannabinoids, prior to the 

accident. Preliminary toxicology reports 

indicated that the individual did not 

have any alcohol or other illegal 

substances in his system. 

Detailed chemical analyses by DEA 

and other investigators have found these 

synthetic cannabinoids spiked on plant 

material in herbal incense products 

marketed to the general public. Product 

analyses have found variations in both 

the synthetic cannabinoid found on the 

plant material and the amount. As 

proposed in scientific literature, the risk 

of adverse health effects is further 

increased by the fact that similar 

products vary in the composition and 

concentration of synthetic cannabinoids 

spiked on the plant material. 

Self-reported abuse of these THC-like 

synthetic cannabinoids either alone 

(e.g., in pills with the substance in 

powder form) or spiked on plant 

material appear extensively on Internet 

discussion boards, and abuse has been 

reported to public health officials and 

law enforcement. The abuse of these 

substances spiked on plant material is 

corroborated by forensic laboratory 

analysis of products encountered by law 

enforcement. 

According to the U.S. Customs and 

Border Protection, a number of the 

products and synthetic cannabinoids 

appear to originate from foreign sources. 

Product manufacturing operations 

encountered by law enforcement 

corroborate that the herbal incense 

products are manufactured in the 

absence of quality controls and devoid 

of regulatory oversight. Law 

enforcement has encountered the 

manufacture of herbal incense products 

occurring in such places as residential 

neighborhoods. These products and 

associated synthetic cannabinoids are 

readily accessible via the Internet. 

Based on the above data, the 

continued uncontrolled manufacture, 

distribution, importation, exportation, 

and possession of JWH–018, JWH–073, 

JWH–200, CP–47,497, and 

cannabicyclohexanol pose an imminent 

hazard to the public safety. DEA is not 

aware of any recognized therapeutic 

uses of these synthetic cannabinoids in 

the United States. 

DEA has considered the three criteria 

for placing a substance into Schedule I 

of the CSA (21 U.S.C. 812). The data 

available and reviewed for JWH–073, 

JWH–018, JWH–200, CP47,497, and 

cannabicyclohexanol indicate that these 

synthetic cannabinoids each has a high 

potential for abuse, no currently 

accepted medical use in treatment in the 

United States and a lack of accepted 

safety for use under medical 

supervision. 

In accordance with the provisions of 

section 201(h) of the CSA (21 U.S.C. 

811(h)) and 28 CFR 0.100, the 

Administrator has considered the 

available data and the three factors 

required to support a determination to 

temporarily schedule five synthetic 

cannabinoids: 1-butyl-3-(1- 

naphthoyl)indole, 1-pentyl-3-(1- 

naphthoyl)indole, 1-[2-(4- 

morpholinyl)ethyl]-3-(1- 

naphthoyl)indole, 5-(1,1- 

dimethylheptyl)-2-[(1R,3S)-3- 

hydroxycyclohexyl]-phenol, and 5-(1,1- 

dimethyloctyl)-2-[(1R,3S)-3- 

hydroxycyclohexyl]-phenol in Schedule 

I of the CSA and finds that temporary 

placement of these synthetic 

cannabinoids into Schedule I of the CSA 

is necessary to avoid an imminent 

hazard to the public safety. 

Regulatory Requirements 

With the issuance of this final order, 

JWH–018, JWH–073, JWH–200, CP– 

47,497, and cannabicyclohexanol 

become subject to the regulatory 

controls and administrative, civil and 

criminal sanctions applicable to the 

manufacture, distribution, possession, 

importation, and exportation of a 

Schedule I controlled substance under 

the CSA. 

1. Registration. Any person who 

manufactures, distributes, dispenses, 

imports, exports, or possesses JWH–018, 

JWH–073, JWH–200, CP–47,497, or 

cannabicyclohexanol or who engages in 

research or conducts instructional 

activities with respect to JWH–018, 

JWH–073, JWH–200, CP–47,497, or 

cannabicyclohexanol, or who proposes 

to engage in such activities, must be 

registered to conduct such activities in 

accordance with 21 U.S.C. 823 and 958. 

Any person who is currently engaged in 

any of the above activities and is not 

registered with DEA must submit an 

application for registration and may not 

continue their activities until DEA has 

approved that application. Retail sales 

of Schedule I controlled substances to 

the general public are not allowed under 

the Controlled Substances Act. 

2. Security. JWH–018, JWH–073, 

JWH–200, CP–47,497, and 

cannabicyclohexanol are subject to 

Schedule I security requirements. 

Accordingly, appropriately registered 

DEA registrants must manufacture, 

distribute and store these substances in 

accordance with 1301.71; 1301.72(a), 

(c), and (d); 1301.73; 1301.74; 1301.75(a) 

and (c); and 1301.76 of Title 21 of the 

Code of Federal Regulations as of March 

1, 2011. 

3. Labeling and packaging. All 

labeling and packaging requirements for 

controlled substances set forth in Part 

1302 of Title 21 of the Code of Federal 

Regulations shall apply to commercial 

containers of JWH–018, JWH–073, JWH– 

200, CP–47,497, and 

cannabicyclohexanol. Current DEA 

registrants shall have thirty (30) 

calendar days from the effective date of 

this Final Order to be in compliance 

with all labeling and packaging 

requirements. 

4. Quotas. Quotas for JWH–018, JWH– 

073, JWH–200, CP–47,497, and 

cannabicyclohexanol will be established 

based on registrations granted and quota 

applications received pursuant to part 

1303 of Title 21 of the Code of Federal 

Regulations. 

5. Inventory. Every DEA registrant 

who possesses any quantity of JWH– 

018, JWH–073, JWH–200, CP–47,497, or 

cannabicyclohexanol is required to keep 

inventory of all stocks of these 

substances on hand pursuant to 

1304.03, 1304.04, and 1304.11 of Title 

21 of the Code of Federal Regulations. 

Every current DEA registrant who 

desires registration in Schedule I for 

JWH–018, JWH–073, JWH–200, CP– 

47,497, or cannabicyclohexanol shall 

conduct an inventory of all stocks of 

these substances. Current DEA 

registrants shall have thirty (30) 

calendar days from the effective date of 

this Final Order to be in compliance 

with all inventory requirements. 

6. Records. All registrants who handle 

JWH–018, JWH–073, JWH–200, CP– 

mstockstill on DSKH9S0YB1PROD with RULES

11078 Federal Register / Vol. 76, No. 40 / Tuesday, March 1, 2011 / Rules and Regulations 

47,497, or cannabicyclohexanol are 

required to keep records pursuant to 

1304.03, 1304.04, 1304.21, 1304.22, and 

1304.23 of Title 21 of the Code of 

Federal Regulations. Current DEA 

registrants shall have thirty (30) 

calendar days from the effective date of 

this Final Order to be in compliance 

with all recordkeeping requirements. 

7. Reports. All registrants are required 

to submit reports in accordance with 

1304.33 of Title 21 of the Code of 

Federal Regulations. Registrants who 

manufacture or distribute JWH–018, 

JWH–073, JWH–200, CP–47,497, or 

cannabicyclohexanol are required to 

comply with these reporting 

requirements and shall do so as of 

March 1, 2011. 

8. Order Forms. All registrants 

involved in the distribution of JWH– 

018, JWH–073, JWH–200, CP–47,497, or 

cannabicyclohexanol must comply with 

order form requirements of part 1305 of 

Title 21 of the Code of Federal 

Regulations as of March 1, 2011. 

9. Importation and Exportation. All 

importation and exportation of JWH– 

018, JWH–073, JWH–200, CP–47,497, or 

cannabicyclohexanol must be 

conducted by appropriately registered 

DEA registrants in compliance with part 

1312 of Title 21 of the Code of Federal 

Regulations on or after March 1, 2011. 

10. Criminal Liability. The 

manufacture, distribution, dispensation, 

or possession with the intent to conduct 

these activities; possession; importation; 

or exportation of JWH–018, JWH–073, 

JWH–200, CP–47,497, or 

cannabicyclohexanol not authorized by, 

or in violation of the CSA or the 

Controlled Substances Import and 

Export Act occurring as of March 1, 

2011 is unlawful. 

Executive Order 12988 

This final temporary scheduling order 

meets the applicable standards set forth 

in sections 3(a) and 3(b)(2) of Executive 

Order 12988 Civil Justice Reform. 

Executive Order 13132 

This final temporary scheduling order 

does not preempt or modify any 

provision of State law; nor does it 

impose enforcement responsibilities on 

any State; nor does it diminish the 

power of any State to enforce its own 

laws. Accordingly, this order does not 

have federalism implications warranting 

the application of Executive Order 

13132. 

Congressional Review Act 

Pursuant to section 808(2) of the 

Congressional Review Act, the agency is 

not required to comply with the Act if 

it makes a good faith finding that notice 

and public procedure thereon are 

impracticable, unnecessary, or contrary 

to the public interest. It is in the public 

interest to schedule these cannabinoids 

immediately because they pose a public 

health risk. Use of materials spiked with 

these cannabinoids has been the cause 

of emergency room visits and calls to 

poison control centers. The adverse 

health effects associated with these 

synthetic cannabinoids and their related 

products include agitation, anxiety, 

nausea, vomiting, tachycardia (fast, 

racing heartbeat), elevated blood 

pressure, tremor, seizures, 

hallucinations, paranoid behavior, and 

non-responsiveness. The materials have 

been marketed on products that are 

available to the general public, and their 

manufacture is devoid of quality 

controls and unregulated. 

This temporary scheduling action is 

taken pursuant to section 811(h), which 

is specifically designed to enable DEA 

to act in an expeditious manner to avoid 

an imminent hazard to the public safety 

from new or designer drugs or abuse of 

those drugs. Section 811(h) exempts the 

temporary scheduling order from 

standard notice and comment 

rulemaking procedures to ensure that 

the process moves swiftly. For the same 

reasons that underlie section 811(h), 

that is, DEA’s need to move quickly to 

place these five cannabinoids into 

Schedule 1 because they pose a threat 

to public health, it would be contrary to 

the public interest to delay 

implementation of the temporary 

scheduling order by requiring DEA to 

undertake the procedures necessary to 

comply with the Congressional Review 

Act prior to the order taking effect. 

Unfunded Mandates Reform Act of 1995 

This final temporary scheduling order 

will not result in the expenditure by 

State, local and tribal governments, in 

the aggregate, or by the private sector, of 

$126,400,000 or more (adjusting for 

inflation) in any one year, and it will 

not significantly or uniquely affect small 

governments. Therefore, no actions were 

deemed necessary under the provisions 

of the Unfunded Mandates Reform Act 

of 1995. 

List of Subjects in 21 CFR Part 1308 

Administrative practice and 

procedure, Drug traffic control, 

Reporting and recordkeeping 

requirements. 

Under the authority vested in the 

Attorney General by section 201(h) of 

the CSA (21 U.S.C. 811(h)), the 

Administrator hereby amends 21 CFR 

part 1308 as follows: 

PART 1308—SCHEDULES OF 

CONTROLLED SUBSTANCES 

■ 1. The authority citation for part 1308 

continues to read as follows: 

Authority: 21 U.S.C. 811, 812, 871(b), 

unless otherwise noted. 

■ 2. Section 1308.11 is amended by 

adding new paragraphs (g)(1), (2), (3), 

(4), and (5) to read as follows: 

§ 1308.11 Schedule I. 

* * * * * 

(g) * * * 

(1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)- 

3-hydroxycyclohexyl]-phenol, its 

optical, positional, and geometric 

isomers, salts and salts of isomers— 

7297 (Other names: CP–47,497) 

(2) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3- 

hydroxycyclohexyl]-phenol, its optical, 

positional, and geometric isomers, salts 

and salts of isomers—7298 (Other 

names: cannabicyclohexanol and CP– 

47,497 C8 homologue) 

(3) 1-Butyl-3-(1-naphthoyl)indole, its 

optical, positional, and geometric 

isomers, salts and salts of isomers— 

7173 (Other names: JWH–073) 

(4) 1-[2-(4-Morpholinyl)ethyl]-3-(1- 

naphthoyl)indole, its optical, positional, 

and geometric isomers, salts and salts of 

isomers—7200 (Other names: JWH–200) 

(5) 1-Pentyl-3-(1-naphthoyl)indole, its 

optical, positional, and geometric 

isomers, salts and salts of isomers— 

7118 (Other names: JWH–018 and 

AM678) 

Dated: February 18, 2011. 

Michele M. Leonhart, 

Administrator. 

[FR Doc. 2011–4428 Filed 2–28–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Bureau of Prisons 

28 CFR Part 541 

[Docket No. BOP–1118–F] 

RIN 1120–AB18 

Inmate Discipline Program/Special 

Housing Units: Subpart Revision and 

Clarification 

AGENCY: Bureau of Prisons, Justice. 

ACTION: Final rule; delay of effective 

date. 

SUMMARY: In this document, the Bureau 

of Prisons delays the effective date of 

the final rule that appeared in the 

Federal Register on December 8, 2010, 

(75 FR 76263) and the subsequent 

correction which appeared in the 

mstockstill on DSKH9S0YB1PROD with RULES